Study #2023-0252
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (TalD) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Talquetamab, Daratumumab, Pomalidomide, Dexamethasone
Description
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed or Refractory Multiple Myeloma
Study phase:
Phase III
Physician name:
Jing Ye
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-448-0874
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.